A head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials

Competing Interest Statement

MDZ received honoraria from the University of Southern California Alzheimer's Therapeutic Research Institute and LuMind IDSC Foundation. MSR has received grants/contracts from NIH, Eisai and Eli Lilly. He is a consultant to AC Immune, Alnylam and Ionis. He serves as Data Safety Monitoring Board Chair for Alzheon and Biohaven. He is a Scientific Advisory Board for Embic, Prescient and Positrigo. BTC has received equipment and precursor materials from Cerveau and AVID and is a consultant for Alnylam and LuMind IDSC Foundation.

Funding Statement

The Trial Ready Cohort Down Syndrome (TRCDS) is funded by the National Institute on Aging (1R61AG066543 01). The Alzheimer's Biomarkers Consortium Down Syndrome (ABCDS) is funded by the National Institute on Aging and the National Institute for Child Health and Human Development (U01 AG051406, U01 AG051412, U19 AG068054) and the Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (NIH INCLUDE Project). The work contained in this publication was also supported through the following National Institutes of Health Programs: The Alzheimer's Disease Research Centers Program (P50 AG008702, P30 AG062421, P50 AG016573, P50 AG005133, P50 AG005681, P30 AG062715, P30 AG066519, P30 AG066468 and P30 AG072973), the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers Program (P50 HD105353), the National Center for Advancing Translational Sciences (UL1 TR001873, UL1 TR002373, UL1 TR001414, UL1 TR001857, UL1 TR002345, UL1 TR002366), the National Centralized Repository for Alzheimer Disease and Related Dementias (U24 AG21886), and DS Connect (The Down Syndrome Registry) supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). In Cambridge, UK this research was supported by the NIHR Cambridge Biomedical Research Centre and the Windsor Research Unit, CPFT, Fulbourn Hospital Cambridge, UK. Sampled iterative local approximation algorithm (SILA) methodology is supported by the National Institute on Aging (R01AG080766).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The imaging sites have entered web-based data through the Alzheimer's Therapeutic Research Institute (ATRI) as part of the ABC-DS study. The data that support the findings of this study are openly available in the ABC-DS database (https://ida.loni.usc.edu/login.jsp?project=ABCDS).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes